Asia-Pacific Journal of Clinical Oncology

Scope & Guideline

Elevating clinical practices with cutting-edge research.

Introduction

Welcome to your portal for understanding Asia-Pacific Journal of Clinical Oncology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1743-7555
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2006 to 2024
AbbreviationASIA-PAC J CLIN ONCO / Asia-Pac. J. Clin. Oncol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The Asia-Pacific Journal of Clinical Oncology (APJCO) is dedicated to advancing the field of clinical oncology through rigorous research and innovative studies. The journal focuses on the unique challenges and advancements in cancer care within the Asia-Pacific region, emphasizing the significance of local contexts in treatment and management strategies. The following core areas outline the journal's main aims and scopes:
  1. Clinical Trials and Research Innovations:
    The journal publishes original research and findings from clinical trials, focusing on new therapies, treatment protocols, and patient care methodologies that can enhance clinical practice.
  2. Cancer Epidemiology and Prevention:
    Research on cancer incidence, risk factors, and preventive strategies is a key focus, addressing the unique epidemiological trends in the Asia-Pacific region.
  3. Multidisciplinary Cancer Care:
    APJCO emphasizes the importance of a multidisciplinary approach in cancer treatment, highlighting collaborative efforts among various healthcare professionals to improve patient outcomes.
  4. Health Policy and Access to Care:
    The journal examines health policies affecting cancer care accessibility and affordability, advocating for equitable healthcare solutions in the Asia-Pacific region.
  5. Patient-Centered Care and Quality of Life:
    Research on patient-reported outcomes, quality of life assessments, and supportive care measures is prioritized, ensuring that patient perspectives are integral to cancer treatment planning.
  6. Emerging Technologies in Oncology:
    The integration of novel technologies, such as telemedicine, digital health, and artificial intelligence in oncology practice, is a significant area of exploration for improving cancer care delivery.
The Asia-Pacific Journal of Clinical Oncology is actively addressing emerging trends and themes in cancer research and treatment. These areas reflect the dynamic nature of oncology and the journal's commitment to advancing clinical practice in the region. The following points outline these trending scopes:
  1. Immunotherapy and Targeted Therapies:
    There is a significant increase in research related to immunotherapy and targeted therapies, as these modalities are reshaping treatment paradigms for various cancers, particularly in the context of personalized medicine.
  2. Digital Health and Telemedicine:
    The rise of telemedicine and digital health solutions has gained momentum, especially following the COVID-19 pandemic, leading to increased research on remote patient monitoring, virtual consultations, and digital interventions.
  3. Genomic and Precision Medicine:
    Emerging studies focusing on genomic profiling and precision medicine are trending, highlighting the importance of tailored treatment approaches based on individual genetic profiles.
  4. Health Disparities and Equity in Cancer Care:
    There is a growing interest in understanding and addressing health disparities within cancer care, focusing on equitable access to treatments and outcomes for diverse populations across the Asia-Pacific region.
  5. Palliative Care and Supportive Services:
    Research on palliative care and supportive services is increasingly recognized for its importance in enhancing the quality of life for cancer patients, leading to more publications in this area.

Declining or Waning

As the Asia-Pacific Journal of Clinical Oncology continues to evolve, certain research themes have seen a noticeable decline in publication frequency. These waning scopes may reflect shifts in the focus of ongoing research, changes in clinical priorities, or the maturation of certain fields. The following points highlight these declining themes:
  1. Traditional Chemotherapy Studies:
    There is a decreasing emphasis on conventional chemotherapy studies, likely due to the increasing focus on targeted therapies and immunotherapy, which are becoming the standard of care in many cancer types.
  2. Single-Institution Studies:
    Research publications from single institutions are declining, as there is a growing preference for multicenter collaborations that provide broader data and more robust findings.
  3. Basic Science Research:
    While foundational research remains important, there is a shift towards applied clinical research that directly impacts patient care, causing a decline in purely basic science studies within the journal.
  4. Symptom Management Studies:
    Research focused solely on symptom management, without integration into broader treatment protocols or comprehensive care strategies, is becoming less prevalent, reflecting a shift towards more holistic cancer care approaches.

Similar Journals

JNCI Cancer Spectrum

Advancing cancer research for a brighter tomorrow.
Publisher: OXFORD UNIV PRESSISSN: Frequency: 6 issues/year

JNCI Cancer Spectrum, published by Oxford University Press, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. With an impressive impact demonstrated through its Q1 ranking in both Cancer Research and Oncology categories for 2023, this journal provides a vital platform for disseminating high-quality research and innovative findings in a rapidly evolving landscape. Since its inception in 2017, JNCI Cancer Spectrum has embraced open access, enhancing the accessibility of evidence-based knowledge to researchers, professionals, and students across the globe. Additionally, it boasts notable positions in Scopus rankings, with a strong performance in both the Medicine and Biochemistry, Genetics and Molecular Biology categories. The journal is committed to its objectives of fostering collaborative efforts and encouraging dialogue among experts, making it an essential resource for anyone involved in cancer research.

Frontiers in Oncology

Innovating oncology through open access and collaboration.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

EJSO

Elevating surgical practices with impactful research.
Publisher: ELSEVIER SCI LTDISSN: 0748-7983Frequency: 12 issues/year

The European Journal of Surgical Oncology (EJSO), published by Elsevier Science Ltd, stands as a leading international journal dedicated to the field of surgical oncology. With an ISSN of 0748-7983 and an E-ISSN of 1532-2157, EJSO has been a key resource for researchers and practitioners since its inception in 1985, covering a wide spectrum of topics in advanced surgical techniques, oncology practices, and multidisciplinary approaches to cancer treatment. The journal boasts impressive rankings, being classified in the Q1 quartile for Medicine (Miscellaneous) and Surgery, and Q2 in Oncology for 2023, reflecting its high impact within the scientific community, with a Scopus ranking of #36/551 in Medicine and Surgery, placing it in the 93rd percentile. Although it does not currently offer Open Access options, EJSO remains committed to advancing the field through reliable research and innovative surgical methodologies. Its ongoing contributions are invaluable for those engaged in the continuous improvement of cancer treatment and management.

ONCOLOGY-NEW YORK

Advancing Cancer Research, One Article at a Time.
Publisher: UBM MEDICAISSN: 0890-9091Frequency: 12 issues/year

ONCOLOGY-NEW YORK is a prominent journal dedicated to the field of oncology, published by UBM MEDICA. Since its inception in 1987, the journal has served as a pivotal platform for disseminating groundbreaking research and advancements in cancer treatment, research, and education. With an ISSN of 0890-9091 and an E-ISSN of 2767-7389, it stands as an accessible resource for professionals, researchers, and students alike. The journal currently holds impressive rankings, categorized within Q3 in Oncology and Q4 in Cancer Research for 2023, reflecting its commitment to high-quality research output and contributions to the field. Despite its challenges in Scopus rankings, positioned at #283/404 in Medicine: Oncology and #188/230 in Biochemistry, Genetics, and Molecular Biology: Cancer Research, ONCOLOGY-NEW YORK continues to primarily focus on innovative cancer therapies and emerging clinical research. The journal's ongoing dedication to enhancing knowledge and understanding in oncology makes it a vital resource for all stakeholders invested in combating cancer.

INDIAN JOURNAL OF CANCER

Fostering Collaboration in the Fight Against Cancer
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0019-509XFrequency: 4 issues/year

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.

JCO Oncology Practice

Driving Change in Cancer Care Through Policy and Practice
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2688-1527Frequency: 6 issues/year

JCO Oncology Practice is a premier peer-reviewed journal published by Lippincott Williams & Wilkins, specializing in the intersection of oncology and health policy. Established as a vital resource since 2020, this journal serves as a platform for the dissemination of innovative research, policy analysis, and clinical practice advancements aimed at enhancing cancer care. With its impressive impact factor and recognition in the top quartile (Q1) across multiple categories including Health Policy and Oncology, JCO Oncology Practice ranks #3 in Oncology Nursing and consistently shares cutting-edge insights that drive improvements within the field. The journal is accessible to a broad audience through its open access options, ensuring that vital knowledge reaches practitioners, researchers, and students alike. By prioritizing the latest evidence-based practices and addressing contemporary challenges in cancer treatment, JCO Oncology Practice plays an essential role in shaping the future of oncology practice and policy in the United States and beyond.

BREAST CANCER RESEARCH AND TREATMENT

Leading the Charge in Breast Cancer Innovation
Publisher: SPRINGERISSN: 0167-6806Frequency: 18 issues/year

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Pioneering Research for Tomorrow's Treatments
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0889-8588Frequency: 6 issues/year

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, published by W B SAUNDERS CO-ELSEVIER INC, is a premier journal dedicated to advancing the fields of hematology and oncology. With its ISSN 0889-8588 and E-ISSN 1558-1977, this esteemed publication has been a cornerstone of clinical scholarship since its inception in 1987, providing comprehensive annual updates that bridge the gap between research and clinical practice. Known for its rigorous editorial standards and impactful contributions, the journal holds a respectable Q2 quartile classification in both hematology and oncology as of 2023, ranking it in the 50th percentile among its peers. Although it is not an open-access journal, the content is accessible to institutions and professionals worldwide. As the scope of the journal expands through 2024, it continues to attract an audience of researchers, healthcare professionals, and students who seek to stay informed on the latest advancements, treatment modalities, and groundbreaking studies in the fields of hematology and oncology.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Exploring Breakthroughs in Cancer Science and Patient Care.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

ONCOLOGY REPORTS

Fostering Excellence in Cancer Research
Publisher: SPANDIDOS PUBL LTDISSN: 1021-335XFrequency: 12 issues/year

Oncology Reports is a distinguished journal dedicated to advancing knowledge in the field of oncology. Published by Spandidos Publications Ltd, this journal has been a cornerstone in cancer research since its establishment in 1994 and is set to continue its impactful contributions until 2024. With ISSN 1021-335X and E-ISSN 1791-2431, it ranks in the Q2 category in Cancer Research, Medicine (Miscellaneous), and Oncology as of 2023, reflecting its solid standing in the academic community. The journal's current Scopus rankings position it notably within Medicine (Oncology) (#74/404, 81st percentile) and Biochemistry, Genetics and Molecular Biology (Cancer Research) (#67/230, 71st percentile), underscoring its rigorous peer-review process and the quality of its published research. Although not an open-access journal, Oncology Reports remains committed to disseminating vital information to researchers, professionals, and students, ensuring they stay at the forefront of developments in cancer studies. Its comprehensive scope promotes a multidisciplinary approach, encompassing clinical and experimental aspects of oncology, thus serving as an essential resource for those striving to understand and combat cancer.